MoHealthNet

Smart PA

Drug Monograph

Drug/Drug Class:	**Zilretta® (triamcinolone acetonide) extended-release injectable suspension/Systemic Corticosteroid**
Prepared for:	MO HealthNet
Prepared by:	Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Zilretta® is supplied as one vial of powder, one vial of 5 ml diluent, and one sterile vial adapter. When reconstituted, it is an injectable suspension that delivers 32 mg of triamcinolone acetonide.
Manufacturer:	Flexion Therapeutics, Inc., Burlington, MA 01803
Indications:	Zilretta® is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee.
Costs:	$270 per vial of Zilretta®. Wholesale Acquisition Cost
Summary of Findings:	MO HealthNet Division recommends Open Access status for this product.
Status Recommendation:	☐ Prior Authorization (PA) Required ☒ Open Access ☐ Fiscal Edit ☐ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☐ Under Solicitation ☐ Appropriate Indications ☒ No PA Required

Prepared By: Luke Boehmer PharmD
Date: May 18, 2018

© 2018 Conduent Business Services, LLC All Rights Reserved.